多索茶碱治疗替格瑞洛相关呼吸困难的疗效及安全性

Efficacy and Safety of Doxofylline in the Treatment of Ticagrelor-Related Dyspnea

目的探讨多索茶碱治疗替格瑞洛相关呼吸困难的疗效及安全性。方法选择本院于2016年2月至2018年2月收治的替格瑞洛相关呼吸困难84例作为研究资料,随机分组各42例,对照组给予安慰剂治疗,观察组给予多索茶碱治疗,观察两组治疗效果及心血管不良事件发生率。结果观察组治疗有效率92.86%与对照组61.90%比较明显更高,P<0.05;疗前和治疗后,两组患者血小板聚集率比较均无明显差异,P>0.05。结论针对替格瑞洛相关呼吸困难采用多索茶碱治疗可有效缓解症状,且安全性较高,不会增加心血管不良事件发生率,值得推广应用。

Objective To investigate the efficacy and safety of doxofylline in the treatment of ticagrelor-related dyspnea. Methods 84 cases of ticagrelor-related dyspnea admitted to our hospital from February 2016 to February 2018 were selected as the study data. 42 patients were randomly divided into groups. The control group was given placebo treatment. The observation group was treated with doxofylline. The treatment effect and the incidence of cardiovascular adverse events were observed. Results The effective rate of treatment in the observation group was 92.86% compared with 61.90% in the control group, P<0.05. There was no significant difference in platelet aggregation rate between the two groups before and after treatment, P> 0.05. Conclusion The treatment of ticagrelor-related dyspnea with doxofylline can effectively alleviate the symptoms, and it is safer and does not increase the incidence of cardiovascular adverse events. It is worthy of popularization and application.